Amy Shapiro

Medical Director
Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA

Presentation(s):

• LB 01.2 - Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• OC 30.5 - Emicizumab Prophylaxis for the Treatment of People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 6 Study

  Monday, July 11, 2022
  11:45 AM – 12:00 PM

• PB0555 - Hypoplasminogenemia: an International retroSpecTive and prOspective cohoRt studY (HISTORY): the international registry of patients with plasminogen deficiency

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1159 - The Atlanta Study: Emicizumab and simoctocog alfa in previously untreated/minimally treated patients and in patients with inhibitors

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM